Russian innovative drugs hold over 60% of domestic market by units
Quick Look
- Russian innovative drugs now constitute over 60% of the domestic pharmaceutical market in terms of units sold, according to Industry and Trade Minister Anton Alikhanov.
- However, their share in value terms is only about 20%.
AI-generated summary
Why It Matters
Russian Industry and Trade Minister Anton Alikhanov stated that innovative drugs produced in Russia now make up over 60% of the domestic market in terms of units. However, their share in value terms is significantly lower, at just over 20%. The minister emphasized the importance of increasing the proportion of highly profitable innovative drugs and stimulating innovation within the Russian pharmaceutical sector.
PODOLSK, May 21. /TASS/. Russian innovative drugs account for over 60% of the domestic pharmaceutical market, Industry and Trade Minister Anton Alikhanov told reporters.
"But our main focus should probably be on innovative drugs. <…> Because, if we are talking in terms of units, we already account for over 60% of the Russian market," he said.
However, in value terms, this share is just over 20%. According to the minister, it is important to increase the share of highly profitable innovative drugs, which international companies sell at whatever prices they want due to the lack of alternatives.
"It is crucial to stimulate the innovation process in our pharma sector," the Industry and Trade Minister emphasized.
He also recalled that the ministry is preparing support measures for companies registering drugs that meet first-in-class requirements.
What to Watch
AI outlook — possibilities, not facts
The Ministry of Industry and Trade will announce specific support measures for companies registering first-in-class drugs.
Likely · Within months
Open Questions
- What specific support measures are being prepared for companies registering first-in-class drugs?
- What are the main reasons for the significant gap between unit share and value share for Russian innovative drugs?
- What is the projected timeline for increasing the value share of domestic innovative drugs?
- Which specific innovative drugs are contributing most to the unit share?
